Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that BBS7 downregulation in occlusal hypofunctional periodontal ligament tissue is associated with reduced Sonic hedgehog signaling activity, potentially playing a key role in maintaining PDL homeostasis.

This study reports on biofeedback treatment for dysfunctional voiding in three adult cases, providing insights into this condition when diagnosed beyond childhood.

This study found that hidradenitis suppurativa significantly impaired quality of life in German patients, with severity linked to skin and certain extra-cutaneous changes, but not reduced by surgical or conventional medicamentous treatments.

This study indicates that the EQ-5D-5L may not effectively capture the burden of alopecia areata on patients' health-related quality of life, and suggests that alternative measures might better assess treatment benefits related to hair regrowth.

This review discusses hair abnormalities in various epidermolysis bullosa subtypes and reports no new clinical findings.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

This source explores the potential use of oral bicalutamide for treating female pattern hair loss, but specific results or outcomes from the study are not reported in the abstract.

This study found that BBS7 is crucial for maintaining Shh signaling and periodontal ligament homeostasis, with occlusal hypofunction leading to its downregulation and impacting cell migration and angiogenesis.

This article critically analyzed the trajectory of the Anais Brasileiros de Dermatologia over the past decade, reporting that the journal has experienced notable growth in bibliometric indices, suggesting a successful editorial policy and increased international visibility compared to Brazilian and other international dermatology journals.

Among men with androgenetic alopecia, this study found that taking 5 mg of KX-826 twice daily significantly increased hair count compared to a placebo, with the treatment being well-tolerated and no serious adverse effects reported.

This article discusses the BJUI's strategies to support urology-related clinical trials but reports no new experimental results; the authors emphasize the importance of rigorous trial design and reporting standards.

In this Baquba city study, alopecia areata was more prevalent among males aged 21 to 30, with most experiencing single lesions on the head, recurring cases, and a history of psychological stress.

This study found that bicalutamide mesotherapy resulted in subtle hair density improvements and was well tolerated by premenopausal women with androgenetic alopecia.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

This collection of interdisciplinary studies highlights research from various institutions on topics relevant to Brazilian social development, but it reports no new empirical findings.

This study found that BBS7 expression is crucial for maintaining Sonic hedgehog signaling and periodontal ligament homeostasis in occlusal hypofunctional conditions.

This study suggests that the downregulation of BBS7 in occlusal hypofunctional periodontal ligament impairs Shh signaling, which is essential for maintaining periodontal ligament homeostasis.

This study found that downregulation of BBS7 in periodontal ligament cells was associated with reduced Sonic hedgehog signaling, which plays a crucial role in maintaining PDL homeostasis.

In this case report, a 38-year-old woman experienced progressive lightening of a blue-green eyebrow tattoo treated with a QS ruby laser, but eyebrow hair density reduction was noted as a potential adverse effect.

This report detailed the British Hair and Nail Society's national grand round, which aids in diagnosing and treating complex hair disorders, showcasing rare diagnoses and suggesting novel therapies.

This study found that alopecia areata and androgenetic alopecia moderately affected the quality of life of Chinese patients, with younger individuals and those experiencing hair loss for over a year reporting higher impact.

This study found that adults with atopic dermatitis who were treated with baricitinib at doses of 2mg or 4mg experienced significant improvements in work productivity, potentially leading to substantial indirect cost savings for employers over 16 weeks.

This study found that the PQ-70 shampoo formulation demonstrated the highest Hair Humidity Resistance Factor, indicating superior anti-frizz performance compared to other tested shampoos.

This case report describes a 40-year-old woman with Birt-Hogg-Dubé syndrome diagnosed with multiple chromophobe renal cell carcinomas, highlighting the importance of recognizing associated dermatologic lesions for early intervention.

This review explores how seborrheic dermatitis impacts patients' quality of life but does not present new research findings; it highlights a need for further studies on influencing factors.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

This study concluded that qianliekang combined with liuweidihuangwan is a more economical treatment for benign prostatic hyperplasia compared to finasteride plus tamsulosin.

This study demonstrates that Bazi Bushen capsules may have therapeutic potential against skin photoaging in mice by enhancing NRF2 expression and targeting the KEAP1-NRF2 pathway.

This report describes a patient with biotinidase deficiency presenting bilateral optic atrophy, and confirms autosomal recessive inheritance through enzyme dosage analysis in the patient and family members.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.